Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer

Lung Cancer: Targets and Therapy

Volumn 7, Issue , 2016, Pages 35-44

  Minami, Seigo ^a   Ogata, Yoshitaka ^a   Ihara, Shouichi ^a   Yamamoto, Suguru ^a   Komuta, Kiyoshi ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

Author keywords

First line chemotherapy; Overall survival; Retrospective study; Second line chemotherapy; Small cell lung cancer; Third line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER;

EID: 84964059146     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: 10.2147/LCTT.S100184     Document Type: Article

References (37)

1. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008;22(13):1486–1492
2. Kuo YH, Lin ZZ, Yang YY, et al. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012;82(1):19–24
3. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis. Onco Targets Ther. 2013;6:1493–1500
4. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–5447
5. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–4019
6. Travis WD, Brambilla E, Müller-Hermelink HK, et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004:31–34
7. National Cancer Institute, Cancer Therapy Evaluation Program [homepage on the Internet], Common Toxicity Criteria, Version 2.0 [published 1999 April 30]Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed March 12, 2016
8. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247
11. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969;46(4):516–525
12. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med. 2015;236(4):297–304
13. Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer. Med Oncol. 2014;31(12):323
14. Holgersson G, Sandelin M, Hoye E, et al. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol. 2012;29(5):3176–3182
15. Inomata M, Hayashi R, Tokui K, et al. Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy. Tumori. 2014;100(5):507–511
16. Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung Cancer. 2014;86(1):91–95
17. Hermes A, Waschki B, Reck M. Hyponatremia as prognostic factor in small cell lung cancer – a retrospective single institution analysis. Respir Med. 2012;106(6):900–904
18. Christodolou C, Pavlidis N, Samantas E, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res. 2002;22(6b):3749–3757
19. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol. 1997;27(3):158–165
20. Jin Y, Sun Y, Shi X, Zhao J, Shi L, Yu X. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. J Cancer Res Ther. 2014;10(suppl):C160–C166
21. Garassino MC, Torri V, Michetti G, et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011;72(3):378–383
22. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458
23. Khakwani A, Rich AL, Tata LJ, et al. Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit. PLoS One. 2014;9(2):e89426
24. Parsons HM, Harlan LC, Stevens JL, Ullmann CD. Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J. 2014;20(2):97–104
25. Froeschl S, Nicholas G, Gallant V, Laurie SA. Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer. J Thorac Oncol. 2008;3(2):163–169
26. Imai H, Mori K, Wakuda K, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med. 2015;10(1):61–66
27. de Jong WK, ten Hacken NH, Groen HJ. Third-line chemotherapy for small cell lung cancer. Lung Cancer. 2006;52(3):339–342
28. Simos D, Sajjady G, Sergi M, et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin Lung Cancer. 2014;15(2):110–118
29. Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol. 2013;8(10):1272–1281
30. Arinc S, Gonlugur U, Devran O, et al. Prognostic factors in patients with small cell lung carcinoma. Med Oncol. 2010;27(2):237–241
31. Hong S, Cho BC, Choi HJ, et al. Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. Oncology. 2010;79(3–4):293–300
32. Kim YH, Goto K, Yoh K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer. 2008;113(9):2518–2523
33. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866–872
34. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J. 2012;53(1):111–117
35. Hermes A, Gatzemeier U, Waschki B, Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – a retrospective single institution analysis. Respir Med. 2010;104(12):1937–1942
36. Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111(3):452–460
37. Asai N, Ohkuni Y, Matsunuma R, Nakashima K, Iwasaki T, Kaneko N. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy. J Cancer Res Ther. 2012;8(2):266–271.